Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02086604 · ClinicalTrials.gov registry record · Phase 1
Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell Lymphoma
A Phase 1 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 37
- Enrollment target
NCT02086604 is a Phase 1 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 37 participants.
The verdict
NCT02086604, a Phase 1 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 37 participants
- Enrollment target
Study Summary
This Phase I clinical trial studies the side effects and maximum tolerated dose (MTD) of the combination of brentuximab vedotin (BV) and lenalidomide in the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Interventions
- DRUG Lenalidomide
- DRUG Brentuximab vedotin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2014-09-18 |
| Est. Completion | 2022-01-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02086604
The ClinicalTrials.gov registry entry for NCT02086604 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lenalidomide is the first listed.
NCT02086604 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02086604 about?
NCT02086604 is a clinical study titled "Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell Lymphoma". This Phase I clinical trial studies the side effects and maximum tolerated dose (MTD) of the combination of brentuximab vedotin (BV) and lenalidomide in the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
What is the current status of trial NCT02086604?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2014-09-18. Estimated completion is 2022-01-12.
What interventions are being tested in trial NCT02086604?
The interventions under investigation include: Lenalidomide (DRUG), Brentuximab vedotin (DRUG).
Who is sponsoring clinical trial NCT02086604?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.